Literature DB >> 6131302

Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

M A Karmali, B T Steele, M Petric, C Lim.   

Abstract

A cytotoxin active on Vero cells, less active on hela cells, and inactive on WI38 cells (Vero toxin [VT]) was detected in stool isolates of Escherichia coli from 8 of 15 sporadic cases of haemolytic uraemic syndrome (HUS). Stools from 5 of these 8 patients were examined for faecal VT activity, and all were positive. Of the 7 of 15 patients who did not have VT+ E. coli, 2 were positive for faecal VT, and a third (patient K) had strong serological evidence of VT+ E. coli infection. 2 HUS patients, including patient F, had siblings with uncomplicated diarrhoea who had both VT+ E. coli in the stools and faecal VT activity. Thus 11 of 15 (73%) of the HUS cases had evidence of infection by VT+ E. coli, suggesting that there was an association between these organisms and these cases of HUS. The clustering of 2 HUS patients and their siblings with VT+ E. coli accords with this suggestion, as do the rising titres of VT-neutralising antibody in 2 HUS patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6131302     DOI: 10.1016/s0140-6736(83)91795-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  278 in total

1.  Effects of Shiga toxin 2 on lethality, fetuses, delivery, and puerperal behavior in pregnant mice.

Authors:  K Yoshimura; J Fujii; A Tanimoto; T Yutsudo; M Kashimura; S Yoshida
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Escherichia coli O157:H7 in beef cattle presented for slaughter in the U.S.: higher prevalence rates than previously estimated.

Authors:  L J Gansheroff; A D O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

3.  Toxicity of Shiga toxin 1 in the central nervous system of rabbits.

Authors:  J Fujii; Y Kinoshita; T Yutsudo; H Taniguchi; T Obrig; S I Yoshida
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Evidence of persisting serum antibodies to Escherichia coli O157 lipopolysaccharide and Verocytotoxin in members of rural communities in England.

Authors:  J Evans; R M Chalmers; H Chart; R L Salmon; S M Kench; T J Coleman; D Meadows; P Morgan-Capner; P Softley; M Sillis; D R Thomas
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

Review 5.  Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.

Authors:  Tania N Petruzziello-Pellegrini; Philip A Marsden
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

6.  Outbreak of Escherichia coli O157:H7 infection in a large family.

Authors:  K Ludwig; H Ruder; M Bitzan; S Zimmermann; H Karch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

7.  Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Authors:  Jun Fujii; Mariko Naito; Takashi Yutsudo; Sohkichi Matsumoto; Daniel P Heatherly; Takeshi Yamada; Hideyuki Kobayashi; Shin-Ichi Yoshida; Tom Obrig
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

8.  Use of clustered regularly interspaced short palindromic repeat sequence polymorphisms for specific detection of enterohemorrhagic Escherichia coli strains of serotypes O26:H11, O45:H2, O103:H2, O111:H8, O121:H19, O145:H28, and O157:H7 by real-time PCR.

Authors:  Sabine Delannoy; Lothar Beutin; Patrick Fach
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

Review 9.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Cholestatic jaundice in the haemolytic-uraemic syndrome: a case report.

Authors:  G Jeffrey; C C Kibbler; R Baillod; K Farrington; M Y Morgan
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.